Capital change notice – performance share rights

Template
Capital Change Notice

Updated as at February 2025

Please do not amend or delete individual rows. As this template relates to prescribed content, changes to content
should only be made where it is clearly indicated that this is permitted, otherwise, if an Issuer considers a particular
element does not apply, mark the row as N/A. Any other changes to this prescribed form must first be approved by
NZX as required under NZX Listing Rule 3.26.1.

Section 1: Issuer information
Name of issuer Ryman Healthcare Limited
NZX ticker code RYM
Class of financial product Unquoted performance share rights
ISIN (If unknown, check on NZX website) NZRYME0001S4
Currency NZD
Section 2: Capital change details
Number issued/acquired/redeemed 16,295
Nominal value (if any) N/A
Issue/acquisition/redemption price per security Nil
Nature of the payment (for example, cash or other
consideration)
16,295 of the performance share rights
granted to senior executives under the
LTIP vest on 31 August 2026, and convert
into 16,295 Ordinary Shares at such time,
for no cash consideration.

These share rights are the final tranche of
rights granted as part of the transition from
the previous leadership share scheme,
with time-based vesting conditions only.
Further details of the LTIP and such
performance share rights are provided in
RYM’s annual report.
Amount paid up (if not in full) Fully Paid
Percentage of total class of Financial Products
issued/acquired/redeemed/ (calculated on the
number of Financial Products of the Class,
excluding any Treasury Stock, in existence)
1

0.001604%
For an issue of Convertible Financial Products or
Options, the principal terms of Conversion (for
example the Conversion price and Conversion date
and the ranking of the Financial Product in relation
to other Classes of Financial Product) or the Option
(for example, the exercise price and exercise date)
N/A
Reason for issue/acquisition/redemption and
specific authority for issue/acquisition/redemption/
(the reason for change must be identified here)
Vesting and exercise of 16,295 of the
performance share rights under the LTIP
(see details above) authorised by a board
resolution dated 31 August 2026.

1
The percentage is to be calculated immediately before the issue, acquisition, redemption or Conversion.

Total number of Financial Products of the Class
after the issue/acquisition/redemption/Conversion
(excluding Treasury Stock) and the total number of
Financial Products of the Class held as Treasury
Stock after the issue/acquisition/redemption.
1,015,745,376 Ordinary Shares (excluding
Treasury Stock)

Nil Treasury Stock
In the case of an acquisition of shares, whether
those shares are to be held as treasury stock
N/A
Specific authority for the issue, acquisition, or
redemption, including a reference to the rule
pursuant to which the issue, acquisition, or
redemption is made
Board resolution dated 31 August 2026;
permitted under NZX Listing Rule 4.6.1
Terms or details of the issue, acquisition, or
redemption (for example: restrictions, escrow
arrangements)
Ordinary Shares ranking equally with the
existing Ordinary Shares on issue in RYM
Date of issue/acquisition/redemption
2
31 August 2026
Section 3: Disclosure required for Placements made under Rule 4.5.1
[Issuers may opt to release Section 3 information (if not already done so) in a separate announcement within five Business Days of
the issuance. Delete this Section 3 if capital change is not the result of a Placement under Rule 4.5.1]

Details of the approach in identifying investors who
were able to participate in the offer and how their
respective allocations in the offer were determined.

The explanation must set out the key objectives
and criteria the Issuer adopted in the allocation
process, whether one of those objectives was a
best effort to allocate on a pro rata basis to existing
holders of the Issuer’s Equity Securities, and any
significant exceptions or deviations from those
objectives and criteria.
N/A
Section 4: Authority for this announcement and contact person
Name of person

authorised to make this
announcement
Morgan Powell
Contact person for this announcement Morgan Powell
Contact phone number +64 21 246 6361
Contact email address morgan.powell@rymanhealthcare.com
Date of release through MAP

31 August 2026




2
Continuous issuers using this form in reliance on Rule 3.13.2, please indicate the period during which the relevant
issue/acquisition/redemptions were made (for example, 1 January 2019 to 31 January 2019).